AnaptysBio, Inc. Form 4 Filings

Lizzul Paul F. reported acquisition or exercise transactions in this Form 4 filing.

ANAPTYSBIO, INC reported that Chief Medical Officer Paul F. Lizzul received a grant of 16,667 Performance Stock Units on March 12, 2026. These performance-based units were earned after achievement of certified criteria, each representing a right to one share of common stock. The award vests 50% on March 12, 2027 and 50% on March 12, 2028, subject to his continued service, leaving him with 16,667 PSUs held directly.

Faga Daniel reported acquisition or exercise transactions in this Form 4 filing.

AnaptysBio, Inc. reported that President and CEO Daniel Faga received a grant of 53,334 performance stock units (PSUs), each representing one share of common stock. The PSUs were earned based on certified performance criteria and vest over two years: 50% on March 12, 2027 and 50% on March 12, 2028, subject to his continued service.

ANAPTYSBIO director John P. Schmid exercised restricted stock units into common shares. On June 15, 2026 he converted 6,030 RSUs into 6,030 shares of common stock for no cash consideration. Following the transaction, he holds 37,652 common shares directly, with no remaining RSU position reported.

AnaptysBio director Renton Hollings reported a routine equity compensation event. On June 15, 2026, he exercised 6,030 restricted stock units (RSUs), receiving 6,030 shares of common stock for no cash consideration, as each RSU converts into one share upon settlement.

Following this RSU settlement, Hollings directly holds 10,995 shares of AnaptysBio common stock. The RSU award vested 100% on June 15, 2026, conditioned on continued service through the vesting date, so this transaction reflects compensation vesting rather than an open‑market purchase or sale.

ANAPTYSBIO director John A. Orwin exercised restricted stock units into common shares. On June 15, 2026, he converted 6,030 restricted stock units into 6,030 shares of common stock at no cash cost, increasing his directly held stake to 16,695 shares.

Each RSU represents a right to receive one share of common stock upon settlement. The RSU award was structured to vest 100% on June 15, 2026, contingent on Mr. Orwin’s continued service to the company through that date. The filing reports no share sales, tax withholding, or gifts in connection with this transaction.

Hughes Owen reported acquisition or exercise transactions in this Form 4 filing.

ANAPTYSBIO director Owen Hughes received a grant of restricted stock units (RSUs). On May 11, 2026, he was awarded 11,250 RSUs, each representing a contingent right to receive one share of common stock for no cash payment upon settlement.

One third of these RSUs will vest on May 11, 2027, with the remaining two thirds vesting in equal annual installments, provided he continues to serve the company on each vesting date. After this grant, his reported RSU holdings from this award total 11,250 units held directly.

Murphy Christopher M. reported acquisition or exercise transactions in this Form 4 filing.

AnaptysBio, Inc. reported a compensation-related equity grant to its Chief Financial Officer, Christopher M. Murphy. On May 11, 2026, he received 25,765 restricted stock units, each representing a right to receive one share of common stock for no cash consideration.

The RSUs vest in four equal annual installments of 25% each, starting on May 11, 2027, as long as he continues providing service to the company on each vesting date. Following this grant, Murphy holds 25,765 RSUs directly.

GRAY SUSANNAH reported acquisition or exercise transactions in this Form 4 filing.

AnaptysBio director Susannah Gray received a grant of 11,250 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of AnaptysBio common stock for no cash consideration upon settlement.

One third of the RSUs vest on April 27, 2027, with the remaining units vesting in equal annual installments, as long as Gray continues providing services to the company on each vesting date.

ANAPTYSBIO, INC President and CEO Daniel Faga reported a disposition of derivative securities. He returned 11,000 employee stock options, each exercisable for one share of common stock at $31.12 per share, to the issuer. The filing notes the option was fully vested and exercisable, and this was a non-market disposition back to the company rather than an open-market trade.

ANAPTYSBIO, INC director John A. Orwin reported option adjustments tied to a corporate separation. On April 20, 2026, he received several stock option grants for 8,250, 16,510, 16,510, 10,600, and 3,311 underlying AnaptysBio common shares at exercise prices between $10.87 and $32.17 per share, while corresponding options with higher exercise prices were disposed of back to the issuer.

Footnotes explain that, under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was adjusted into options for both companies, leading to these new AnaptysBio option positions. Some options are fully vested and exercisable, while others vest monthly starting February 6, 2026.

AnaptysBio director John P. Schmid reported multiple stock option adjustments tied to a corporate separation. On the reported date, he received several option grants to buy AnaptysBio common stock and simultaneously disposed of corresponding options back to the issuer.

A footnote explains that, following a pro rata distribution under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was split into an option for First Tracks shares and an option for AnaptysBio shares. As a result, Schmid acquired new AnaptysBio options in amounts determined under that agreement. One referenced stock option is fully vested and exercisable, while another vests in 1/12 monthly installments starting on February 6, 2026, contingent on his continued service.

ANAPTYSBIO director Renton Hollings reported a series of stock option adjustments tied to a corporate separation. On April 20, 2026, he acquired multiple new options to buy AnaptysBio common stock and simultaneously disposed of corresponding older options back to the issuer. The footnotes explain that, following a pro rata distribution under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was split into options over both companies’ shares. These are compensation and structural option changes, all held directly, and involve derivatives only rather than open-market trades in common stock.

ANAPTYSBIO, INC President and CEO Daniel Faga reported compensation-related stock option changes rather than open-market share trades. On April 20, 2026, he both acquired and disposed of multiple employee stock options covering shares of AnaptysBio common stock.

Footnotes explain that, following a pro rata distribution under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was adjusted so it became an option on both companies’ shares. As a result, Faga acquired new options to buy AnaptysBio common stock at exercise prices such as $10.87, $15.53, $17.02, $22.31, and $32.17 per share, with corresponding dispositions of prior awards back to the issuer.

Several of these options are described as fully vested or vesting 25% on specific January dates with the balance vesting in equal monthly installments over 48 months, contingent on his continued service. The filing reflects grants, adjustments, and issuer-related dispositions of options, not open-market buying or selling of common stock.

ANAPTYSBIO director John P. Schmid sold 20,645 shares of Common Stock in open-market transactions. All sales occurred on March 30, 2026 at weighted average prices ranging from $55.7087 to $57.3989 per share, within overall trade ranges of $55.20 to $57.92.

After these sales, Schmid directly holds 31,622 shares of ANAPTYSBIO Common Stock, according to the filing.

ANAPTYSBIO, INC President and CEO Daniel Faga received 34,300 performance-based restricted stock units (PSUs) after the compensation committee certified that specific performance goals were achieved on March 25, 2026. Each PSU represents a right to receive one share of common stock.

On March 27, 2026, Faga sold an aggregate of 17,679 shares of common stock in multiple open-market transactions at weighted-average prices ranging from the mid‑$50s to mid‑$60s per share. According to the disclosure, these sales were solely to cover tax withholding obligations from the PSU vesting and were not discretionary trades.

After these grant and tax-related sales, Faga holds 495,965 shares of AnaptysBio common stock directly, indicating that the transactions reflect routine compensation vesting and associated tax settlement rather than a change in his core equity position.

LOUMEAU ERIC J reported multiple insider transaction types in a Form 4 filing for ANAB. The filing lists transactions totaling 30,000 shares at a weighted average price of $41.85 per share. Following the reported transactions, holdings were 35,000 shares.

AnaptysBio director Magda Marquet reported an option exercise and related share sales. On January 15, 2026, she exercised a fully vested stock option for 11,000 shares of common stock at an exercise price of $26.11 per share, increasing her direct holdings to 20,930 shares. That same day, she sold 9,290 shares of common stock at a weighted average price of $48.1162 per share, in multiple trades between $47.595 and $48.54, and an additional 1,710 shares at a weighted average price of $48.849 per share, in trades between $48.625 and $48.88. After these transactions, she directly owned 9,930 shares of common stock and held additional options to purchase up to 70,104 shares of common stock that vest according to their terms.

AnaptysBio Chief Medical Officer Paul F. Lizzul reported routine equity activity. On January 7, 2026, 8,525 restricted stock units (RSUs) converted into the same number of common shares for no cash cost, reflecting scheduled vesting. The RSU award is set to vest 25% per year starting January 7, 2026, as long as he continues providing services.

On January 8, 2026, he sold 3,650 shares of AnaptysBio common stock at $44.71 per share. The footnotes state this was a “sell to cover” transaction to satisfy tax withholding obligations tied to the RSU vesting, and was not a discretionary sale. After these transactions, he directly held 42,088 shares of common stock and 25,575 RSUs.

AnaptysBio, Inc. reported insider equity activity by its Chief Financial Officer, Dennis Mulroy. On January 7, 2026, 6,700 restricted stock units (RSUs) were settled into an equal number of common shares for no cash consideration, increasing his directly held common stock to 24,367 shares. The RSU award vests in 25% increments annually starting January 7, 2026, subject to continued service.

On January 8, 2026, he sold 2,515 common shares at $44.71 per share to cover tax withholding obligations related to the RSU vesting, described as a non-discretionary “sell to cover” transaction. After these transactions, he directly held 21,852 common shares and 20,100 RSUs.

AnaptysBio chief legal officer Eric Loumeau reported RSU vesting and a related tax sale of shares. On January 7, 2026, 5,888 restricted stock units were converted into the same number of shares of AnaptysBio common stock at an exercise price of $0, reflecting that each RSU settles into one share for no cash consideration. After this transaction, Loumeau held 15,045 shares of common stock directly.

On January 8, 2026, he sold 2,210 shares of common stock at a price of $44.71 per share. The filing explains that this sale was executed solely to cover tax withholding obligations arising from the RSU vesting through a “sell to cover” transaction and was not a discretionary sale. Following the sale, Loumeau directly owned 12,835 shares of common stock and 17,662 RSUs that continue to vest in 25% annual increments starting January 7, 2026, contingent on continued service.

AnaptysBio President and CEO Daniel Faga, who is also a director, reported the vesting of 26,838 restricted stock units (RSUs) on January 7, 2026. Each RSU converts into one share of common stock for no cash cost, increasing his directly held common shares to 493,625 and leaving 80,512 RSUs outstanding.

On January 8, 2026, Faga reported selling 14,281 shares of common stock at $44.71 per share. According to the disclosure, this sale was made solely to cover tax withholding obligations arising from the RSU vesting through a “sell to cover” transaction, and was not a discretionary trade.

AnaptysBio, Inc.’s chief legal officer Eric J. Loumeau reported equity award activity and related share sales. On January 6, 2026, 5,545 restricted stock units (RSUs) were settled into the same number of common shares for no cash consideration, and he received a new grant of 17,100 RSUs plus a stock option for 23,200 shares with a $43.91 exercise price.

On January 7, 2026, he reported several sales of common stock at weighted average prices around the mid‑$40s per share, including blocks such as 2,017 shares at $45.11 and 5,281 shares at $45.3839. Footnotes state that some shares were sold to cover tax withholding on RSU vesting and that the transactions were executed under a Rule 10b5‑1 trading plan. Following these transactions, he directly held 9,157 common shares.

AnaptysBio, Inc. Chief Medical Officer Paul F. Lizzul reported multiple equity transactions. On January 6, 2026, 6,145 restricted stock units (RSUs) converted into the same number of common shares for no cash cost, and his common stock holdings became 39,448 shares. That day he also received 21,400 new RSUs and a stock option for 29,000 shares.

The new RSUs vest 25% per year starting January 6, 2027, while the option vests 25% on January 6, 2027 and then monthly in equal installments, all contingent on continued service. On January 7, 2026, he sold 2,235 common shares at $45.11 solely to cover tax withholding from the RSU vesting, leaving 37,213 common shares owned directly.

AnaptysBio, Inc. reported insider equity activity by President and CEO Daniel Faga. On January 6, 2026, 17,850 restricted stock units (RSUs) were converted into the same number of shares of common stock for no cash consideration. On January 7, 2026, 9,202 shares of common stock were sold at $45.11 per share to cover tax withholding obligations related to RSU vesting, described as a non-discretionary “sell to cover” transaction.

Also on January 6, 2026, Faga received new equity awards consisting of 98,600 RSUs and a stock option for 133,400 shares with an exercise price of $43.91. The RSUs and option awards vest over several years, subject to continued service. After these transactions, Faga beneficially owned 466,787 shares of AnaptysBio common stock directly.

AnaptysBio, Inc. Chief Financial Officer Dennis Mulroy reported equity compensation activity and a related share sale. On January 6, 2026, 5,245 restricted stock units settled into common stock, and he then beneficially owned 19,575 common shares. On January 7, 2026, he sold 1,908 common shares at $45.11 per share to cover tax withholding tied to the RSU vesting, which the company notes was a non-discretionary sell-to-cover transaction, leaving him with 17,667 common shares.

On January 6, 2026, he also received new grants of 21,400 restricted stock units and 29,000 stock options with a $43.91 exercise price. The 21,400 RSUs vest 25% annually starting January 6, 2027, and the option vests 25% on January 6, 2027, then monthly in equal installments until fully vested, in each case contingent on continued service.

AnaptysBio director Dennis M. Fenton reported new equity awards. On January 6, 2026, he received a stock option for 5,500 shares of AnaptysBio common stock at an exercise price of $43.91 per share, held directly. The option vests in equal monthly installments of 1/12 of the total shares starting on February 6, 2026, conditioned on continued service.

On the same date, he was also granted 4,000 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock for no cash consideration. These RSUs vest in full on the date of AnaptysBio’s 2027 annual meeting of shareholders, subject to his continued service to the company.

AnaptysBio director Rita Jain reported new equity awards. On January 6, 2026, she received a stock option covering 5,500 shares of AnaptysBio common stock with an exercise price of $43.91 per share. According to the disclosure, this option vests in equal monthly installments of 1/12 of the total shares starting on February 6, 2026, so long as she continues to provide services to the company.

The filing also shows a grant of 4,000 restricted stock units (RSUs), each representing the right to receive one share of common stock for no cash consideration upon settlement. These RSUs are scheduled to vest 100% on the date of AnaptysBio’s 2027 annual meeting of shareholders, again conditioned on continued service. After these awards, Jain beneficially owns 5,500 stock options and 4,000 RSUs directly.

AnaptysBio director Magda Marquet reported new equity awards from the company. On January 6, 2026, she received a stock option to buy 5,500 shares of AnaptysBio common stock at an exercise price of $43.91 per share. This option vests in equal 1/12 installments each month starting on February 6, 2026, as long as she continues providing service to the company on each vesting date.

On the same date, she was also granted 4,000 restricted stock units (RSUs), each representing the right to receive one share of common stock for no cash consideration upon settlement. These RSUs vest as to 100% of the total award on the date of AnaptysBio’s 2027 annual meeting of shareholders, contingent on her continued service through that date.

AnaptysBio, Inc. director Renton Hollings received new equity awards on January 6, 2026. He was granted a stock option for 5,500 shares of AnaptysBio common stock at an exercise price of $43.91 per share, with no purchase price for the grant itself. This option vests in equal monthly installments of 1/12 of the total shares starting on February 6, 2026, so long as he continues to provide service on each vesting date.

He was also granted 4,000 restricted stock units (RSUs), each representing the right to receive one share of common stock for no cash consideration upon settlement. These RSUs vest as to 100% of the 4,000 units on the date of AnaptysBio’s 2027 annual meeting of shareholders, subject to his continued service through that date.

AnaptysBio, Inc. reported a Form 4 for director John P. Schmid detailing new equity compensation awards. On January 6, 2026, he received a stock option covering 5,500 shares of common stock with an exercise price of $43.91 per share. This option vests in equal monthly installments of 1/12 starting February 6, 2026, so long as he continues providing service to the company.

Schmid was also granted 4,000 restricted stock units (RSUs), each representing the right to receive one share of AnaptysBio common stock for no cash payment. These RSUs vest 100% on the date of the company’s 2027 annual meeting of shareholders, contingent on his continued service through that date.

AnaptysBio, Inc. granted equity awards to director Ware J. Anthony. On 01/06/2026, he received a stock option for 5,500 shares of common stock with a $43.91 exercise price and no upfront cost. The option vests in 12 equal monthly installments of 1/12 each, starting on February 6, 2026, as long as he continues providing service to the company on each vesting date.

On the same date, he was also granted 4,000 restricted stock units. Each RSU represents a right to receive one share of AnaptysBio common stock for no consideration. All 4,000 RSUs are scheduled to vest in full on the date of AnaptysBio’s 2027 annual meeting of shareholders, subject to his continued service through that date.

AnaptysBio, Inc. director John A. Orwin reported new equity awards on a Form 4. On January 6, 2026, he was granted a stock option covering 8,250 shares of common stock with an exercise price of $43.91 per share. This option vests in equal monthly installments of 1/12 of the total shares starting on February 6, 2026, as long as he continues providing service to the company on each vesting date.

On the same date, he also received 6,000 restricted stock units (RSUs), each representing the right to receive one share of common stock for no cash consideration. These RSUs vest as to 100% of the total units on the date of AnaptysBio’s 2027 annual meeting of shareholders, subject to his continued service. Both the option and RSUs are reported as held directly.

AnaptysBio, Inc. President and CEO Daniel Faga reported equity transactions in a Form 4. On January 3, 2026, 34,677 restricted stock units (RSUs) were converted into the same number of shares of common stock at an exercise price of $0, reflecting RSU vesting. Each RSU represents a right to receive 1 share of common stock upon settlement for no consideration.

On January 5, 2026, Faga sold 15,309 shares of common stock at $43.26 per share. According to the footnote, this sale was made solely to cover tax withholding obligations through a “sell to cover” transaction and did not represent a discretionary sale. After these transactions, Faga directly beneficially owned 458,139 shares of common stock and 69,355 RSUs.

AnaptysBio, Inc. chief financial officer Dennis Mulroy reported the vesting of 8,292 restricted stock units on January 3, 2026, which converted into the same number of common shares at no cost upon settlement. Following this, his directly held common stock position increased to 17,693 shares.

On January 5, 2026, he sold 3,363 shares of AnaptysBio common stock at a price of $43.26 per share to cover tax withholding obligations related to the RSU vesting, described as a non-discretionary “sell to cover” transaction. After the sale, he directly held 14,330 shares of common stock and 16,585 RSUs, which continue to vest in 25% annual installments beginning January 3, 2025, subject to continued service.

AnaptysBio Chief Medical Officer Paul F. Lizzul reported routine equity activity involving vested RSUs and a related share sale. On January 3, 2026, 10,555 restricted stock units were converted into the same number of shares of common stock at an exercise price of $0, increasing his directly held common stock to 37,522 shares. Each RSU represents the right to receive 1 share of common stock for no cash consideration.

On January 5, 2026, he sold 4,219 shares of common stock at $43.26 per share, leaving him with 33,303 directly owned shares. According to the disclosure, this sale was executed solely to cover tax withholding obligations from the RSU vesting through a "sell to cover" transaction and is described as not a discretionary transaction. The RSUs vest 25% annually starting January 3, 2025, subject to his continued service.

AnaptysBio chief legal officer Eric Loumeau reported RSU vesting and a related share sale. On January 3, 2026, 7,287 restricted stock units converted into an equal number of AnaptysBio common shares at an exercise price of $0, reflecting previously granted equity that vested. The RSUs vest 25% per year starting on January 3, 2025, as long as he continues providing services to the company.

On January 5, 2026, Loumeau sold 2,983 common shares at $43.26 per share. According to the disclosure, this sale was a “sell to cover” transaction used solely to satisfy tax withholding obligations tied to the RSU vesting and was not a discretionary trade. After these transactions, he held 13,251 AnaptysBio common shares directly and 14,575 RSUs representing additional potential shares upon future vesting.

AnaptysBio, Inc.'s Chief Medical Officer reported an equity transaction involving company stock. On 12/22/2025, the officer exercised 1,500 employee stock options at an exercise price of $18.50 per share and acquired the same number of common shares. On the same date, the officer sold 1,500 shares of common stock at a price of $50.00 per share. After these transactions, the officer directly owned 26,967 shares of AnaptysBio common stock and held 83,500 stock options from the reported grant.

The filing notes that the sale was made under a Rule 10b5-1 trading plan adopted on April 14, 2025, which is a pre-arranged plan for trading shares. It also states that the reported stock option is fully vested and that the officer holds additional options to purchase up to an aggregate of 394,810 shares of common stock, which vest according to their terms.

AnaptysBio’s chief legal officer reported option exercises and share sales. On December 16–18, 2025, the officer exercised employee stock options to buy common stock at $14.02 and $20.16 per share, then sold portions of the resulting shares in several trades.

Sales were made under a pre-arranged Rule 10b5-1 trading plan, with weighted average sale prices including $44.6756, $45.2369 and $46.00 per share. After these transactions, the officer directly owned 8,947 shares of common stock and held fully vested options covering 53,000 shares, plus additional options to purchase up to 414,810 shares that vest according to their terms.

AnaptysBio, Inc. reported an insider stock transaction by its Chief Financial Officer. On 12/16/2025, the CFO exercised an employee stock option to buy 10,000 shares of common stock at an exercise price of $20.16 per share, increasing directly held shares.

That same day, the CFO sold 9,365 shares at a weighted average price of $44.6152 per share and 6,360 shares at a weighted average price of $45.2062 per share under a pre-arranged Rule 10b5-1 trading plan adopted on April 11, 2025. After these transactions, the CFO directly owned 15,761 and then 9,401 shares of common stock and continued to hold 70,600 vested stock options reported in the table, plus additional options to purchase up to an aggregate of 339,440 shares that vest according to their terms.

Eric J. Loumeau, Chief Legal Officer of AnaptysBio, Inc. (ANAB), reported both purchases and sales of company common stock on 09/30/2025. He acquired 5,000 shares by exercising employee stock options at an exercise price of $14.02 and an additional 1,325 shares under the company ESPP included in the reported holdings, bringing his post-transaction direct ownership to 17,328 shares. He also sold 8,240 shares at $29.00 per share under a 10b5-1 trading plan adopted April 11, 2025.

The Form 4 shows he retains outstanding options to purchase 68,000 shares exercisable under the option described and additional unvested options aggregating up to 422,310 shares that vest per their terms. Transactions were routine insider activity documented under Section 16 reporting rules.